Jessup J M, Posner M, Huberman M
Department of Surgery, New England Deaconess Hospital, Boston, Massachusetts.
Semin Surg Oncol. 1993 Jan-Feb;9(1):27-32. doi: 10.1002/ssu.2980090106.
Carcinoma of the pancreas has an especially grim prognosis. Only 1-3% of patients survive for 5 years. Radical pancreaticoduodenectomy, especially for minimal disease, is currently the only chance for cure. While radiation therapy does not improve overall survival, it may improve local control following radical resection and decrease pain in locally advanced cancers. Although chemotherapy has led to significant improvements in survival in patients with locally advanced disease, the overall effect is small. When surgery, radiotherapy, and chemotherapy are administered to localized carcinomas in randomized, prospective trials, survival is significantly lengthened. Similar trials in locally advanced, unresectable pancreatic cancer also confirm the concept of synergistic interaction between therapies. Thus, pancreas carcinoma is one neoplasm where multimodality therapy has had a demonstrable, although small effect.
胰腺癌的预后特别严峻。只有1%至3%的患者能存活5年。根治性胰十二指肠切除术，尤其是针对微小病变的患者，是目前唯一的治愈机会。虽然放射治疗并不能提高总体生存率，但它可能会改善根治性切除后的局部控制，并减轻局部晚期癌症的疼痛。尽管化疗已使局部晚期疾病患者的生存率有了显著提高，但总体效果仍较小。在随机、前瞻性试验中，对局限性癌患者进行手术、放疗和化疗时，生存期会显著延长。在局部晚期、无法切除的胰腺癌患者中进行的类似试验也证实了不同治疗方法之间协同作用的概念。因此，胰腺癌是一种多模式治疗虽有明显效果但作用较小的肿瘤。
